The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 15, 2017

Filed:

Aug. 13, 2015
Applicants:

Darwin J. Prockop, Philadelphia, PA (US);

Joo Youn OH, Seoul, KR;

Barry Berkowitz, Framingham, MA (US);

Gavin W. Roddy, Rochester, MN (US);

Robert Rosa, Holland, TX (US);

Inventors:

Darwin J. Prockop, Philadelphia, PA (US);

Joo Youn Oh, Seoul, KR;

Barry Berkowitz, Framingham, MA (US);

Gavin W. Roddy, Rochester, MN (US);

Robert Rosa, Holland, TX (US);

Assignees:

The Texas A&M University System, College Station, TX (US);

Temple Therapeutics, Inc., Framingham, MA (US);

Scott & White Healthcare, Temple, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/28 (2015.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C12N 5/0775 (2010.01); C07K 16/18 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 35/28 (2013.01); A61K 9/0048 (2013.01); A61K 9/0051 (2013.01); A61K 38/1709 (2013.01); A61K 39/00 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); C07K 16/18 (2013.01); C12N 5/0663 (2013.01); A61K 2035/124 (2013.01); C07K 2317/76 (2013.01); C12N 2501/25 (2013.01); C12N 2501/48 (2013.01);
Abstract

The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.


Find Patent Forward Citations

Loading…